Neurointerventional Device Update: The Burgeoning Stroke Toolbox
The treatment of acute ischemic stroke and brain aneurysms is rapidly evolving. New transcatheter devices and adjuvant imaging promising to improve outcomes and reduce the burden of neurovascular disease. However, to really spur this market, long-term, large-scale clinical trials are needed.
You may also be interested in...
International Briefs: NICE On Sutureless Aortic Valves, Mechanical Clot Retrieval, Microsphere Cancer Therapy
In recent guidance documents, the U.K.’s National Institute for Health and Care Excellence offers tempered support for sutureless aortic valve replacement, and calls mechanical clot retrieval in stroke patients unproven and risky. Also, its support for radioactive microspheres for liver cancer depends on malignancy type.
Innovation is driving double-digit growth in the neurointerventional device market as an increasing number of medical device manufacturers develop newer, more effective devices for treating acute ischemic stroke. As new, stent-like retrieval systems and other next-generation neurothrombectomy devices hit the US market in the next few years, competition in this sector will also heat up as manufacturers try to differentiate their devices and jockey for a piece of the market, which is projected to reach almost $70 million by 2015.
Acute ischemic stroke used to be a device category that promised a slow but certain death for start-ups. But there's lots of life in the market, as evidenced by a recent wave of consolidation. Meanwhile, hemorrhagic stroke companies have been perfecting the treatment of cerebral aneurysms.